Protalix BioTherapeutics, Inc. — fact timeline

Protalix BioTherapeutics, Inc. updated its the first quarter ended March 31, 2026 guidance (reaffirmed).

“Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026”

Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.

“On March 18, 2026, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025 and provided a business and clinical update.”

Eyal Rubin resigned as Senior Vice President and Chief Financial Officer at Protalix BioTherapeutics, Inc..

“On April 21, 2025, Eyal Rubin, Sr. Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), provided the Company and the Company’s Board of Directors with six months’ notice of his resignation from his position with the Company and its subsidiary, in order to pursue other opportunities.”

Protalix BioTherapeutics, Inc.: Amended and restated Bylaws to increase special meeting ownership threshold to 25%, modify timing, enhance procedural requirements for stockholder proposals and nominations, adopt universal proxy rules, remove written consent, and add exclusive forum provisions (effective 2024-12-27).

“On December 27, 2024, the Board of Directors of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), unanimously approved and adopted an amendment and restatement of the Bylaws of the Company, effective immediately (the “Amended Bylaws”) to, among other things: (i) amend the criteria relating to stockholders’ ability to call special meetings including (a) increasing the requisite aggregate beneficial ownership of the requesting stockholders from no less than 10% to no less than 25% of all of the votes entitled to be cast on any issue proposed to be considered at the special meeting, (b) modifying the time in which the Company’s secretary will fix the date of such special meeting from not less than 10 days to not less than 30 days after the receipt of such stockholder request, (c) modifying the time in which the stockholders making such request can set the special meeting date from seven days to 10 days following the receipt of such request if the Company’s secretary”

Protalix BioTherapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

“Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.”

Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.

“On March 14, 2024, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2023 and provided a business update.”

Protalix BioTherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

“On November 6, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.”

Zeev Bronfeld retired as Chairman of the Board at Protalix BioTherapeutics, Inc..

“Zeev Bronfeld, the Company’s current Chairman of the Board, has notified the Company of his retirement from the Company for personal reasons, effective as of the same date.”

Eliot Richard Forster was appointed as Chairman of the Board at Protalix BioTherapeutics, Inc..

“On September 12, 2023, Protalix BioTherapeutics, Inc. (the “Company”) announced the appointment by its Board of Directors of Eliot Richard Forster, Ph.D. as Chairman of the Company’s Board of Directors effective as of September 14, 2023.”

Protalix BioTherapeutics, Inc. reported financial results for three months ended June 30, 2023.

“On August 7, 2023, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.”

Protalix BioTherapeutics, Inc. shareholders approved Approval of adjournment of the 2023 Annual Meeting to July 13, 2023 to provide additional time to solicit proxies for a charter amendment at the 2023-06-28 meeting.

“The adjournment was approved by a vote of 39,819,471 shares of Common Stock, with no shares voting against the adjournment or abstaining”

Protalix BioTherapeutics, Inc. shareholders approved Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-28 meeting.

“(5) Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited For Against Abstain 36,781,844 2,683,094 354,533”

Protalix BioTherapeutics, Inc. shareholders approved Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan at the 2023-06-28 meeting.

“(4) Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan ​ For ​ Against ​ Abstain Broker Non-Votes 25,811,597 6,921,213 108,665 8,872,021”

Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers at the 2023-06-28 meeting.

“(3) Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers ​ ​ One Year ​ Two Years ​ Three Years ​ Abstain Broker Non-Votes 30,261,982 600,162 825,319 1,154,012 8,872,021”

Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2023-06-28 meeting.

“(2) Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers ​ For ​ Against ​ Abstain Broker Non-Votes 26,186,630 4,269,510 491,310 8,872,021”

Protalix BioTherapeutics, Inc. shareholders approved Election of Directors at the 2023-06-28 meeting.

“(1) Election of Directors ​ For ​ Withheld Broker Non-Votes Zeev Bronfeld 30,118,208 2,723,267 8,872,021 Dror Bashan 30,175,739 2,665,736 8,872,021 Amos Bar Shalev 30,118,524 2,722,951 8,872,021 Shmuel “Muli” Ben Zvi, Ph.D. 30,614,690 2,226,785 8,872,021 Pol F. Boudes, M.D. 30,619,760 2,221,715 8,872,021 Gwen A. Melincoff 30,517,556 2,323,919 8,872,021 Aharon Schwartz, Ph.D. 30,659,904 2,181,571 8,872,021”

Protalix BioTherapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue Revenues from selling goods of $5.1 million and revenues from license and R&D services of $4.5 million, net income Net loss of approximately $3.1 million, EPS loss of $0.05 per share.

“First Quarter 2023 Financial Highlights ● The Company recorded revenues from selling goods of $5.1 million during the three months ended March 31, 2023, a decrease of $3.9 million, or 43%, compared to revenues of $9.0 million for the three months ended March 31, 2022. The decrease resulted primarily from a decrease of $2.7 million in sales to Brazil and a decrease of $1.1 million in sales to Pfizer, both resulting from timing differences. ● The Company recorded revenues from license and R&D services of $4.5 million for the three months ended March 31, 2023, a decrease of $2.6 million, or 37%, compared to revenues of $7.1 million for the three months ended March 31, 2022. Revenues from license and R&D services are comprised primarily of revenues the Company recognized in connection with the Chiesi Agreements. ● Cost of goods sold was $3.1 million for the three months ended March 31, 2023, a decrease of $2.9 million, or 48%, from cost of goods sold of $6.0 million for the three months en”

Protalix BioTherapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at shares of common stock with aggregate offering price of up to $20,000,000 (effective 2023-02-27).

“On February 27, 2023, Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, as the Company’s sales agent (the "Agent").”

Protalix BioTherapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $25.3 million.

“Committee. Financial Results For the year ended December 31, 2022, compared to the year ended December 31, 2021 ● The Company recorded revenues from selling goods of $25.3 million for the year ended December 31, 2022, an increase of $8.6 million, or 51%, compared to revenues of $16.7 million for the year ended December 31, 2021. The increase resulted from”

Protalix BioTherapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

“On November 14, 2022, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and provided a business update on recent corporate and regulatory developments.”

Shmuel Ben Zvi was appointed as Director at Protalix BioTherapeutics, Inc..

“On June 29, 2022, the Board of Directors of Protalix BioTherapeutics, Inc. (the "Company") appointed Shmuel Ben Zvi, Ph.D. to serve on the Company’s Board of Directors, effective as of the adjournment of the Company’s 2022 Annual Meeting of Stockholders held on June 30, 2022 (the "Meeting").”